北方药学
北方藥學
북방약학
JOURNAL OF NORTH PHARMACY
2014年
11期
37-38,39
,共3页
荨麻疹%慢性%左西替利嗪%沙利度胺
蕁痳疹%慢性%左西替利嗪%沙利度胺
담마진%만성%좌서체리진%사리도알
Urticaria%Chronic%Levocetirizine%Thalidomide
目的:观察分析应用盐酸左西替利嗪联合沙利度胺对于慢性荨麻疹进行治疗的临床疗效,为临床治疗寻求依据。方法:选择我院收治的且经其他方式治疗未取得理想效果的慢性荨麻疹患者作为研究对象并进行分组治疗研究,治疗组均应用左西替利嗪联合沙利度胺进行治疗,对照组均应用盐酸左西替利嗪进行治疗。两组研究对象均进行持续4周的治疗,并于1月后进行随访评价,将具体疗效进行对比分析。结果:治疗组总有效率为72.29%,显著高于对照组的33.82%。组间比较差异具有统计学意义(P<0.05)。两组患者不良反应情况差异不具有显著性(P>0.05)。结论:应用盐酸左西替利嗪联合沙利度胺对慢性荨麻疹进行治疗,具有较好的临床疗效,不良反应率低,患者耐受性好,满意度高,有利于患者尽快康复,具有极大的推广价值。
目的:觀察分析應用鹽痠左西替利嗪聯閤沙利度胺對于慢性蕁痳疹進行治療的臨床療效,為臨床治療尋求依據。方法:選擇我院收治的且經其他方式治療未取得理想效果的慢性蕁痳疹患者作為研究對象併進行分組治療研究,治療組均應用左西替利嗪聯閤沙利度胺進行治療,對照組均應用鹽痠左西替利嗪進行治療。兩組研究對象均進行持續4週的治療,併于1月後進行隨訪評價,將具體療效進行對比分析。結果:治療組總有效率為72.29%,顯著高于對照組的33.82%。組間比較差異具有統計學意義(P<0.05)。兩組患者不良反應情況差異不具有顯著性(P>0.05)。結論:應用鹽痠左西替利嗪聯閤沙利度胺對慢性蕁痳疹進行治療,具有較好的臨床療效,不良反應率低,患者耐受性好,滿意度高,有利于患者儘快康複,具有極大的推廣價值。
목적:관찰분석응용염산좌서체리진연합사리도알대우만성담마진진행치료적림상료효,위림상치료심구의거。방법:선택아원수치적차경기타방식치료미취득이상효과적만성담마진환자작위연구대상병진행분조치료연구,치료조균응용좌서체리진연합사리도알진행치료,대조조균응용염산좌서체리진진행치료。량조연구대상균진행지속4주적치료,병우1월후진행수방평개,장구체료효진행대비분석。결과:치료조총유효솔위72.29%,현저고우대조조적33.82%。조간비교차이구유통계학의의(P<0.05)。량조환자불량반응정황차이불구유현저성(P>0.05)。결론:응용염산좌서체리진연합사리도알대만성담마진진행치료,구유교호적림상료효,불량반응솔저,환자내수성호,만의도고,유리우환자진쾌강복,구유겁대적추엄개치。
Objective:To observe and analyze the application of Levocetirizine Dihydrochloride combined with Thalidomide for the treatment of patients with chronic urticaria, and to seek evidence for the clinical treatment.Method:Patients with chronic urticaria in our hospital,failed to achieve the desired effect with other treatment, were selected for study and treatment in groups. Levocetirizine Dihydrochloride combined with Thalidomide was applied in the treatment group and Levocetirizine Dihydrochloride was applied in the control group. Two groups were treated for 4 weeks and evaluated after a month. Results: The effective rate of the treatment group was 72.29%, significantly higher than the rate of the control group which was 33.82%. The difference between groups was statistically significant (P<0.05). The difference of adverse reactions of the two groups was not statistically significant (P>0.05).Conclusion:Clinical efficacy of Levocetirizine Dihydrochloride combined with thalidomide for the treatment of patients with chronic urticaria was better with low adverse reactions, well tolerance of patients, high satisfaction, and soon recovery of patients.So the method is worth being promoted.